Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
J Clin Exp Hematop. 2022;62(2):79-84. doi: 10.3960/jslrt.22011.
The current consensus on Castleman disease is that it is a group of several distinct lymphoproliferative disorders with different underlying pathogenesis and clinical outcomes. In 1980, Mori et al. proposed the concept of idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia (IPL), a disease of unknown etiology, characterized by severe polyclonal hypergammaglobulinemia and generalized superficial lymphadenopathy. After Frizzera et al.'s landmark report in 1983, the term multicentric Castleman disease (MCD) gradually became established, and for a time, IPL was regarded as identical to MCD. However, with the subsequent recognition of human herpesvirus 8 (HHV8)-related MCD in the 1990s and the contributions by Kojima et al. in the 2000s, in which non-HHV8-related MCD (now called idiopathic MCD) was at least subclassified into IPL and others (non-IPL), it is now clear that the original distinctiveness of IPL is still maintained in MCD, which is a diverse collection of diseases.
目前对于 Castleman 病的共识是，它是一组几种不同的淋巴增生性疾病，具有不同的潜在发病机制和临床结果。1980 年，Mori 等人提出了特发性浆细胞性淋巴结病伴多克隆高丙种球蛋白血症（IPL）的概念，这是一种病因不明的疾病，其特征为严重的多克隆高丙种球蛋白血症和全身性浅表淋巴结病。1983 年 Frizzera 等人的里程碑式报告发表后，多中心 Castleman 病（MCD）的术语逐渐确立，一段时间以来，IPL 被视为等同于 MCD。然而，随着随后在 20 世纪 90 年代认识到人类疱疹病毒 8（HHV8）相关的 MCD，以及 Kojima 等人在 21 世纪的贡献，其中非 HHV8 相关的 MCD（现在称为特发性 MCD）至少被细分为 IPL 和其他（非 IPL），现在很清楚，MCD 中仍然保持着 IPL 的原始独特性，它是一组多种疾病的集合。
